{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-22-000061","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.772133+00:00","generated_at":"2026-06-24T03:29:48.759334+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caladrius Q2 net loss $6.6M; merger with Cend on track for Q3 2022 forming Lisata Therapeutics","bullets":["Net loss $6.6M vs $5.7M YoY; cash $73M after $10M Cend investment.","Merger with Cend expected to close Q3 2022, pending stockholder approval; new ticker LSTA.","HONEDRA pre-consultation with PMDA; XOWNA FREEDOM trial enrollment suspended, interim analysis in Q3.","CLBS201 DKD trial fully enrolled (6 patients), top-line data expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-22-000061","json":"https://secwatch.observer/filing/0000320017-22-000061.json","markdown":"https://secwatch.observer/filing/0000320017-22-000061.md","text":"https://secwatch.observer/filing/0000320017-22-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000061/0000320017-22-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000061/clbs-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:29:48.759334+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}